Immune cells tailored to attack lung cancer show promise in early trial
NCT ID NCT03356808
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial investigates whether specially engineered T cells can safely target and fight lung cancer. Participants have advanced or relapsed lung cancer and receive a single infusion of their own T cells that have been trained to recognize cancer-specific markers. The study aims to check safety and see how long these cells persist in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lung cancer-specific T cells
What this could lead to
If successful, this approach could offer a new treatment option for advanced or relapsed lung cancer by harnessing the immune system to attack tumors.
What could go wrong
This is an early-phase trial with only 20 participants, so results may not apply broadly. Risks include immune reactions or lack of tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••